The Meals and Drug Administration quietly advised wearable maker Whoop final week that it will not take additional enforcement motion over a controversial function that offers customers a studying of their blood stress.
In July 2025, the company warned Whoop for releasing its Blood Strain Insights function with out clearance, saying it was a medical system that required overview. “The product is meant to offer a measurement or estimation of a person’s blood stress, which is inherently related to the prognosis of hypo- and hypertension,” the company wrote.
Whoop countered that the function may very well be launched with out overview as a result of it was supposed for wellness functions and to not diagnose or deal with a illness. “We received’t let regulatory overreach dictate how individuals entry their very own well being information,” CEO Will Ahmed wrote on the time.
This text is unique to STAT+ subscribers
Unlock this text — and get extra evaluation of the applied sciences disrupting well being care — by subscribing to STAT+.
Have already got an account? Log in
View All Plans

